SCHEMBL6033277

SCHEMBL6033277

CSC1(SC)CCOc2c([Se]c3ccc(C(=O)O)cn3)cccc21

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 9/20 0.34
GCK P35557 2/20 0.34
RXRA P19793 4/20 0.32
RXRB P28702 3/20 0.32
RXRG P48443 3/20 0.32
RARA P10276 2/20 0.31
RARB P10826 2/20 0.31
RARG P13631 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PPARG P37231 1/20 0.31
P4HA1 P13674 1/20 0.30
P4HTM Q9NXG6 1/20 0.30
HNF4A P41235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032639 0.84 HNF4A (0.34) RXRARXRBRXRGRARARARB
SCHEMBL6033246 0.80 RARA (0.32) RARARARBRARGCYP1A2CYP2C9
SCHEMBL6882384 0.76 RARB (0.37) RXRARARARARBRARGHNF4A
SCHEMBL7471200 0.74 CYP26A1 (0.36) HCAR3GCKRXRARXRBRXRG
SCHEMBL6033271 0.69 CYP3A4 (0.48) HCAR3GCKRXRARXRBRXRG
SCHEMBL6340991 0.68 RXRA (0.33) RXRARXRBRXRGRARARARB
SCHEMBL8101913 0.68 RARB (0.53) RXRARXRBRXRGRARARARB
SCHEMBL6340318 0.67 RARB (0.37) RXRARXRBRARARARBRARG
SCHEMBL1271404 0.67 CYP3A4 (0.54) RARARARBRARG
SCHEMBL6033044 0.65 RXRA (0.59) RXRARXRBRXRGRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US claimed
EP-1086080-B1 DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2004-08-25 EP claimed
US-6992094-B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-31 US disclosed
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014803-A1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics TYR, DERL1, GPX1 HCAR3 1309/4885GCK 3886/4885RXRA 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.